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Me
Lis
Yo
MaThe PARADIGM-HF (Prospective comparison of ARNi with ACEi to Determine Impact on Global Mortality and Morbidity in
Heart Failure) trial demonstrated that a new angiotensin receptor antagonist-neprilysin inhibitor was superior to an
angiotensin-converting enzyme inhibitor in reducing mortality in patients with heart failure and reduced ejection fraction.
This paper traces the research path that culminated in the development of this drug. The ﬁrst phase, elucidation of the
renin-angiotensin-aldosterone system, began with Tigerstedt’s discovery of renin, followed by isolation of angiotensin,
isolation of angiotensin-converting enzyme, and synthesis of its inhibitors and of angiotensin receptor blockers. Phase 2
began with de Bold’s discovery of atrial natriuretic peptide, followed by isolation of the enzyme that degrades it
(neprilysin) and its inhibitors. Phase 3 consists of blocking both the renin-angiotensin-aldosterone and atrial natriuretic
peptide–degrading systems simultaneously. A molecular complex, LCZ696, developed by scientists at Novartis, combines
an angiotensin receptor blocker with a neprilysin inhibitor, is well tolerated, and represents an important step in the
management of heart failure and reduced ejection fraction. (J Am Coll Cardiol 2015;65:1029–41) © 2015 by the American
College of Cardiology Foundation.“If I have seen further, it is by standing
on the shoulders of giants.”
—Isaac Newton, 1676 (1)
On March 31, 2014, the cardiology world, and many
other medical professionals were excited by the press
statement released by Novartis regarding a clinical
trial on the treatment of heart failure (HF) with a new
drug: “.the Data Monitoring Committee unanimously
recommended early closure of the PARADIGM-HF
[Prospective comparison of ARNi with ACEi to
Determine Impact on Global Mortality and morbidity
in HF trial], indicating patients with chronic heart
failure with reduced ejection fraction [HFrEF] who
received LCZ696 lived longer without being hospital-
ized for heart failure than those who received standard
care with [angiotensin-converting enzyme] inhibitorm the *TIMI Study Group, Cardiovascular Division, Brigham and Women’
dical School, Boston, Massachusetts. Dr. Braunwald serves as a noncomp
ten to this manuscript’s audio summary by JACC Editor-in-Chief Dr. Vale
u can also listen to this issue’s audio summary by JACC Editor-in-Chief D
nuscript received December 29, 2014; revised manuscript received Janua[ACEi] enalapril. Based on the compelling efﬁcacy and
primary endpoint having been met, the trial will now
close early” (2).
In the paper describing the design of the trial,
McMurray et al. (3) outlined a comparison between
LCZ696, a ﬁrst-in-class angiotensin receptor-
neprilysin inhibitor (ARNi), and enalapril. In another
communication, the same authors stated that both
components of the primary endpoint of the trial, car-
diovascular death or hospitalization for HF, would “be
analyzed separately and these additional analyses will
be considered as part of the primary endpoint” (4).
Therefore, there must have been compelling evidence
that, when compared with enalapril in patients with
HFrEF (5), LCZ696 further reduced not only the com-
posite endpoint of cardiovascular death and hospital-
ization for HF, but also cardiovascular death alone.s Hospital, and the Department of Medicine, Harvard
ensated consultant to Novartis.
ntin Fuster.
r. Valentin Fuster.
ry 15, 2015, accepted January 19, 2015.
ABBR EV I A T I ON S
AND ACRONYMS
ACEi = angiotensin-converting
enzyme inhibitor
ADM = adrenomedullin
ANP = atrial natriuretic peptide
ARB = angiotensin
receptor blocker
ARNi = angiotensin receptor
antagonist-neprilysin inhibitor
BNP = B-type natriuretic
peptide
HFrEF = heart failure with
reduced ejection fraction
NEP = neprilysin
NEPi = neprilysin inhibitor
RAAS = renin-angiotensin-
aldosterone system
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1030The results of the PARADIGM-HF trial
were presented at the European Society of
Cardiology on August 30, 2014, and published
simultaneously in the New England Journal
of Medicine (6). It was praised in an accom-
panying editorial by Jessup, who wrote:
“PARADIGM-HF may well represent a new
threshold of hope for patients with heart
failure.The beneﬁcial results seen in
PARADIGM-HF may apply to a wide spectrum
of patients, even those who are currently re-
ceiving the best possible therapy” (7). A per-
spective in the same issue of the New England
Journal of Medicine stated, “We may be
entering a new era of treatment for heart fail-
ure with reduced ejection fraction” (8), strong
words indeed by 2 editors of this journal.
LCZ696 is the ﬁrst of a new class of drugs
that simultaneously block the angiotensin II type I
receptors (angiotensin receptor blocker [ARB]) and
inhibit neprilysin (neprilysin inhibitor [NEPi]), hence,
the acronym ARNi. This dual action places this drug at
the center of 2 critically important systems that have
profound effects on the circulation, as well as on
other tissues: the renin-angiotensin-aldosterone sys-
tem (RAAS), and the natriuretic peptide system (NPS)
(Central Illustration). Although PARADIGM-HF ap-
pears to represent a very important advance in the
treatment of HFrEF, LCZ696 did not burst on the
scene like a comet from outer space, but instead
represents the most recent in a series of brilliant in-
vestigations carried out over more than 11 decades.
The objective of this paper is to summarize the key
steps leading to this new therapy (Figure 1).
RENIN-ANGIOTENSIN-ALDOSTERONE
SYSTEM
In 1898, Finnish physiologist Robert Tigerstedt, who
can be considered to be the ﬁrst giant on whose
shoulders later investigators stood, and his Swedish
medical student Per Bergman, working at the Kar-
olinska Institute in Stockholm, discovered that when
saline extracts of rabbit renal cortex were injected
into rabbits, a pressor response was elicited (9,10)
(Figure 2). They named the active component of the
extract renin, which is now known to be an aspartyl
protease. The next major step in the elucidation of
the RAAS was taken in 1934, when Goldblatt et al. (11)
demonstrated that constriction of the renal arteries of
dogs caused persistent hypertension. Six years later,
2 groups, working in Argentina (12) and in the United
States (13), demonstrated that renin catalyzed the
formation of a peptide pressor substance, laternamed angiotensin. There were 2 forms of the latter, a
largely inactive decapeptide (angiotensin I) that was
cleaved by a second enzyme—a dipeptide hydrolase-
angiotensin converting enzyme (ACE)—to form the
active pressor substance, the octapeptide angiotensin
II (Central Illustration). Subsequently, additional an-
giotensins, the products of further enzymatic hydro-
lysis, were discovered, but they are not central to this
story (14).
In addition to its action on vascular smooth mus-
cle, angiotensin II also causes retention of sodium by
enhancing reabsorption of this ion in the proximal
tubule and by stimulating the release of aldosterone
from the zona glomerulosa of the adrenal cortex,
thereby playing a critical role in the control of extra-
cellular ﬂuid volume and electrolyte balance. Angio-
tensin II also stimulates cell proliferation, oxidative
stress, and ﬁbrosis. The RAAS acts within the blood-
stream, in a classical endocrine mode, and within the
kidneys and other tissues in paracrine (local) and
autocrine (intracellular) modes. ACE also inactivates
the vasodilator peptide, bradykinin, which contrib-
utes to its pressor action, giving the enzyme its
alternate name—kininase II.
RAAS INHIBITORS. As these important actions of
ACE/kininase II became clariﬁed, the search for in-
hibitors of this enzyme was begun. Ferreira made 2
important contributions. First, in 1965, he observed
that the venom of Bothrops Jararaca, the Brazilian pit
viper, contained an inhibitor of the kininase that de-
grades the vasodilator, bradykinin (15). Subsequently,
he reported that this kininase inhibitor also inhibited
ACE (16). He thus showed that the bradykinin poten-
tiating substance and the ACEi were identical. The
earliest ACEi/kininase were synthetic analogues of the
active peptides in the venom and required parenteral
administration. One of these, the nonapeptide,
teprotide, was shown to reduce renal vasoconstric-
tion, lower arterial pressure in hypertensive patients
(17), and improve the disordered hemodynamics in
patients with HF, demonstrating the important role of
activation of the RAAS in the latter (18). Teprotide and
other ACEis, in addition to raising bradykinin levels,
increase the concentration of plasma and urinary
prostaglandins, which are also vasodilators (19).
These favorable effects in patients with hyperten-
sion and with HF stimulated the development of
orally active ACEis, the ﬁrst of which was captopril,
synthesized in 1977 by Ondetti et al. (20), a notable
feat. Captopril soon became a useful antihypertensive
(21). In animal studies, it prevented ventricular
remodeling in rats with myocardial infarction (22) and
reduced all-cause mortality when administered
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The central role of LCZ696 in the dual inhibition of the RAAS and of NEP. Green lines and arrows denote stimulation or activation. Red lines denote
blockade. HFrEF activates both the SNS and the RAAS, which act in concert to increase the release of renin. RAAS acts on angiotensinogen to produce ANG I.
ACE catalyzes the formation of ANG II, which acts on the ATIR, whose biological actions include the release of aldosterone from the adrenal cortex.
b1 receptor blockers, ACEis, ARBs, and MRCBs block the SNS and RAAS at several levels; ACEi also blocks the degradation of bradykinin. The increasing wall
stress in HFrEF activates the NPS with release of ANP and BNP, which in turn activate the NPRA, GC-A, cGMP, and PKG, and result in vasodilation,
natriuresis, diuresis, and ﬁbrosis inhibition. ANP also blocks the release of renin. NEP breaks down ANP, whereas NEPi preserves ANP by blocking NEP.
LCZ696 has 2 components—an ARB and a NEPi, which block RAAS activation while enhancing the adaptive actions of ANP. ACE ¼ angiotensin-converting
enzyme; ACEi ¼ angiotensin-converting enzyme inhibitor; ANG ¼ angiotensin; ANP ¼ atrial natriuretic peptide; ARB ¼ angiotensin receptor blocker; AT1R ¼
angiotensin II type 1 receptor; BNP ¼ brain natriuretic peptide; cGMP ¼ cyclic guanosine monophosphate; GC-A ¼ guanylyl cyclase A; HFrEF ¼ heart failure
with reduced ejection fraction; MRCB ¼ mineralocorticoid receptor blocker; NEP ¼ neprilysin; NEPi ¼ neprilysin inhibitor; NPRA ¼ natriuretic peptide
receptor A; NPS ¼ natriuretic peptide system; PKG ¼ protein kinase G; RAAS ¼ renin angiotensin aldosterone system; SNS ¼ sympathetic nervous system.
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1031long-term to patients with left ventricular dysfunc-
tion following acute myocardial infarction (23). Other
oral ACEis soon followed. Enalapril, the ACEi used as
the comparator in the PARADIGM HF-trial (6), is a
prodrug that is rapidly converted into enalaprilat, its
active form. The latter was shown to prolong survival
in severe HF (24), whereas the prodrug improved
survival in chronic HFrEF (5). ACEis rapidly became,
and remain, ﬁrst-line drugs worldwide for the treat-
ment of both hypertension and HF.Although ACEis are well tolerated by the majority
of patients, an annoying dry cough occurs in 10%
to 15%. A related, but more serious adverse event,
angioedema, can lead to life-threatening obstruc-
tion of the upper airway, and is caused by in-
creased concentrations of bradykinin and vasoactive
prostaglandins consequent to kininase inhibition.
It occurs in 0.1% or 0.2% of Caucasians, but in a
larger percentage of African Americans receiving
ACEis.
FIGURE 1 Timeline of the Path to the PARADIGM HF Trial
angiotensin isolated (12,13) renin discovered (9)
1960
1970
1980
HF mortality ↓ ACEi (24)
20001990 2010
1940
NEP isolated (63)
ACE isolated (16)
ANP discovered (34)
First oral ARB (26) Patent for ARNi (97)
Omapatrilat synthesized (88)
First oral ACEi (20)
NEPi characterized (69)
PARADIGM-HF (6)
1920 1900
Numbers in parentheses refer to text references. ACE ¼ angiotensin-converting enzyme; ACEi ¼ angiotensin-converting enzyme inhibitor;
ANP ¼ atrial natriuretic peptide; ARB ¼ angiotensin receptor blocker; ARNi ¼ angiotensin receptor antagonist-neprilysin inhibitor; HF ¼ heart
failure; NEP ¼ neprilysin; NEPi ¼ neprilysin inhibitor; PARADIGM-HF ¼ Prospective comparison of ARNi with ACEi to Determine Impact on
Global Mortality and morbidity in the Heart Failure.
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1032After it was discovered that the actions of angio-
tensin II are mediated primarily by its type 1 receptor,
a G-protein coupled receptor, the search for compet-
itive blockers of this receptor (ARBs) began (Central
Illustration). Marshall et al. (25) described the ﬁrst of
these, a peptide, in 1970. The angiotensin II analogue,
saralasin, reduced arterial pressure in patients with
malignant or resistant hypertension. Like the ﬁrst
ACEi, it was active only parenterally (26). Timmer-
mans et al. (27) described orally active nonpeptide
ARBs with high afﬁnity. Losartan was the ﬁrst ARB to
be used clinically; a closely related agent, valsartan,
has been shown to improve outcomes in patients
hospitalized for HF by Cohn et al. (28) and is a
component of the ARNi, LCZ696 (6).
Like ACEis, ARBs are potent antihypertensive
agents and are indicated as ﬁrst-line drugs in both
hypertension and HFrEF. However, a major differ-
ence between ACEis and ARBs is the greater speci-
ﬁcity of the latter. Because ARBs do not block the
degradation of kinins, angioedema and persistent
cough are quite uncommon with their use. When
blockade of the RAAS is desired, it is common clinical
practice to begin with an ACEi and switch to an ARB
in patients who are intolerant. Blockers of aldoste-
rone and other mineralocorticoid receptors weredescribed in 1959 (29). By reducing renal sodium
reabsorption, they have a diuretic action and have
also been shown to reduce mortality in patients with
HFrEF (30). These agents are also purported to exert
antiﬁbrotic actions.
NATRIURETIC PEPTIDE SYSTEM
In 1 of the ﬁrst electron microscopic examinations of
mammalian cardiac tissue, Kisch (31), in 1956,
described granules in the atria. In 1978, Adolfo de
Bold (32), another giant, and his collaborators, in
Kingston, Ontario, suggested that these atrial gran-
ules were sites of storage of a protein or polypeptide.
They then observed an inverse relation between
water-electrolyte balance and atrial granularity, with
hypergranularity developing in rats deprived of water
and sodium, and the converse in sodium-loaded rats
(33). In their now classic paper, published in 1981,
they described an experiment that is reminiscent of
the one reported by Tigerstedt and Bergman (9) 83
years earlier (Figures 1 and 2). Their infusion of crude
extracts of rat atrium caused hypotension and a more
than 30-fold increase of sodium excretion, whereas
urine volume rose 10-fold (34). de Bold et al. (32)
named the substance responsible for these effects
FIGURE 2 The Tigerstedt and Bergman Experiments
Robert Adolf Armand
Tigerstedt (ca. 1910)
"A [rabbit] kidney was pulverized with 21 ml of water. Injection into jugular vein.
Within 80 s, there is a rise in mean arterial pressure from 62-67 mmHg to
100 mmHg, i.e. an increase by ca. 50%."
Experiment 1B, November 8, 1896
Tigerstedt and Bergman, Niere und Kreislauf
Skand. Arch. Physiol. 8: 223–271, 1898
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Excerpts from Tigerstedt and Berman’s paper (9), which led to the discovery of renin. Four separate experiments are illustrated. Figure supplied
by M. P. Lefkowitz.
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1033atrial natriuretic factor, which has subsequently been
referred to as atrial natriuretic peptide (ANP). They
isolated and puriﬁed ANP, determined its amino acid
sequence, and developed a radioimmunoassay (35),
establishing the heart to be an endocrine organ (36).
An endocrine function of the heart had, in fact, been
suggested in 1964 (37).
In 1988, Sudoh et al. (38), in the ﬁrst of several
important contributions to this ﬁeld, identiﬁed a
peptide in porcine brain and named it brain natri-
uretic peptide (also known as B-type natriuretic
peptide [BNP]). Although not identical to ANP, BNP
has similar structural, hypotensive, natriuretic, and
diuretic properties. BNP is also present in the heart
and is released primarily from the ventricles (39). A
third peptide in this family, C-type natriuretic pep-
tide (CNP), was also extracted ﬁrst from porcine
brain, and then from endothelial cells (40).
These 3 peptides, which form the natriuretic pep-
tide system (NPS), are the products of separate genes
that encode 3 prohormones. The latter undergo pro-
teolytic cleavage to form the 3 active hormones
having several structural homologies. ANP has 28,
BNP has 32, and CNP has 22 amino acids. ANP and
BNP bind to and activate membrane-bound natri-
uretic peptide receptors-A (Central Illustration). These
are coupled to and activate guanylyl cyclase A, whichincreases the intracellular concentrations of the sec-
ond messenger, cyclic guanosine monophosphate
(41). The latter, in turn, activates protein kinase G,
leading to vasorelaxation, natriuresis, and diuresis
(42). ANP and BNP also inhibit renin secretion (43)
and aldosterone production (44) and attenuate car-
diac and vascular remodeling, apoptosis, ventricular
hypertrophy, and ﬁbrosis (44–47); they also enhance
myocardial relaxation. CNP is released primarily from
endothelial cells, and only trace quantities are found
in the blood. In contrast to ANP and BNP, CNP appears
not to exert a marked effect on sodium or water
excretion, but instead to act as a vasodilator in
paracrine and autocrine modes and to stimulate the
growth of long bones (41,45,48). Although it may
seem inappropriate to label CNP as a “natriuretic”
peptide (NP), all 3 polypeptide hormones are still
widely referred to as NPs, and constitute the NPS.
Distension of the atria and ventricles, as occurs in
cardiac injury and/or overload, ventricular dysfunc-
tion, and HF results in signiﬁcant increases in the
expression of ANP and BNP. In 1986, Burnett (49),
another important investigator in this ﬁeld, and
his collaborators demonstrated elevations of circu-
lating ANP in patients with HF. The concentrations
of circulating BNP and of its inactive precursor,
N-terminal fragment of pro–B-type natriuretic
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1034peptide (NT-proBNP) have become extremely valu-
able in the recognition of hemodynamic overload,
ventricular dysfunction, and HF (50,51). Measure-
ments of these peptides are also useful in assessing
prognosis and monitoring therapy, and appear to be
useful as therapeutic targets as well (52). Although
the infusion of synthetic human ANP, named car-
peritide (53), and human recombinant BNP (nesiri-
tide) have exhibited the desired physiologic effects
(i.e., vasorelaxation, natriuresis, and diuresis) and
have been approved for the treatment of HF in some
countries, they require parenteral administration and
have yet to demonstrate an unambiguous improve-
ment in clinical outcomes (54).
ADRENOMEDULLIN. In 1993, Kitamura et al. (55)
isolated another novel, potent, hypotensive peptide
composed of 52 amino acids from human pheochro-
mocytoma, as well as from normal adrenal medulla,
which they termed adrenomedullin (ADM). Although
it shares the vasorelaxant and natriuretic properties
of ANP and BNP, ADM is structurally unrelated. ADM
has also been shown to reduce myocyte hypertrophy,
ﬁbroblast proliferation, collagen synthesis, and aldo-
sterone secretion. Kitamura developed a sensitive
radioimmunoassay for ADM, reported its presence in
normal human plasma (55), and characterized the
complementary deoxyribonucleic acid encoding the
precursor of the peptide. The vascular endothelium is
now also known to produce ADM, and it is found in
many organs, including the kidney, where it reduces
renal vascular resistance and increases glomerular
ﬁltration rate (56).
Infusion of ADM into normal subjects showed it to
be a potent vasodilator. In patients with HF, it
reduces systemic and pulmonary arterial and wedge
pressures and plasma aldosterone, while raising car-
diac output, urinary volume, and sodium excretion
(57). ADM acts on a speciﬁc receptor, 1 of the so-called
calcitonin gene-related peptide receptors, elevates
intracellular cyclic adenosine monophosphate, and
increases intracellular [Ca2þ], which, in turn, acti-
vates NO synthase and intracellular NO; the latter is
believed to be responsible for the vasodilator action
of ADM (56).
In 1995, Jougasaki et al. (58) reported elevations
of circulating ADM in patients with HF, and plasma
ADM was found to be an independent predictor of
prognosis in such patients. However, the clinical
applicability of ADM measurements has been limited
by the instability of the molecule. An assay for the
midregion of pro-adrenomedullin, the stable pre-
cursor of ADM, was then developed (59). The BACH
(Biomarkers in Acute Heart Failure) study showedmidregion of pro-adrenomedullin to be superior to
NT-proBNP for the prediction of mortality in pa-
tients with acute HF (60). Given the salutary prop-
erties of ADM, it would seem that enhancement
of circulating ADM could be beneﬁcial in patients
with HF.
NEPRILYSIN AND ITS INHIBITION
Circulating NPs are cleared through 2 principal
mechanisms: NP receptor-mediated clearance and
enzyme degradation (61,62). An important paper
published in 1974 by Kerr and Kenny (63) described a
neutral glycosylated zinc endopeptidase in the prox-
imal tubule cells of the rabbit kidney. An equally
important study by Stephenson and Kenny showed
it to be a potent hydrolyzer of ANP (64). The pro-
duction and release of this enzyme from endothelial
cells contributes to its presence in the circulation
(65). The abundance of this peptidase in the renal
cortex contributes to the very brief half-life of ANP
(approximately 2 min in normal human subjects) (66).
Although attention was initially directed to its ability
to hydrolyze ANP (63), this membrane-bound enzyme
with a large extracellular component also degrades
a large number of other vasodilator peptides, in-
cluding ADM (67), and bradykinin, vasoconstrictors
including angiotensins I and II and endothelin-1, as
well as oxytocin, opioid peptides, substance P,
gastrin, vasoactive intestinal peptide, and amyloid
beta protein (68). However, BNP is relatively resistant
to its digestion. Given this enzyme’s broad action
proﬁle, it has had a variety of names, including
atriopeptidase, neutral endopeptidase, EC 3.4.24.11,
enkephalinase, common acute lymphoblastic leuke-
mia antigen, CD10, as well as neprilysin (NEP) (61);
the latter will be the designation used in this paper
(Figure 1).
NEP INHIBITION. In 1980, Roques et al. (69) synthe-
sized thiorphan, a NEPi. Sybertz et al. (70) then
showed that by inhibiting NEP, endogenous ANP
levels rose, and the latter’s natriuretic and diuretic
properties became evident. Similar observations were
made in normal humans (71). In 1995, Ksander et al.
(72) at Ciba-Geigy (which became an important unit
of Novartis) described sacubitril, a NEPi that had su-
perior pharmacologic properties, and which later
became a component of LCZ696. NEPi caused diuresis
in pacing-induced HF in sheep (73) and dogs (74), and
suppressed the activation of aldosterone (75),
demonstrating the important interaction between the
NPS and RAAS. In patients with HF, NEPi lowered
both right atrial and wedge pressures and caused
natriuresis (76).
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1035It was hoped that NEPis would become useful in
the management of hypertension and HF, but these
beneﬁcial effects in patients were modest and were
not seen in all studies (77). In addition to increasing
the concentration of circulating ANP (78), NEPis were
found to increase the concentration of 2 other circu-
lating vasodilators, ADM and bradykinin (78,79).
However, they also increased the concentration of 2
circulating pressors, angiotensin II and endothelin I
(80,81). These 2 opposing actions, that is, inhibition
of degradation of both vasoconstrictor and vasodi-
lator peptides, neutralized each other and, as a
consequence, NEPis alone had little effect on blood
pressure (82) or HF (77).
With the discovery and elucidation of the actions
of NEP and its inhibitors, both the similarities and
differences between the RAAS and the NPS became
clearer (Central Illustration). In normal subjects, the
RAAS is activated, in part, by reduced stretch of the
efferent renal arterioles as well as by stimulation of
beta-1-adrenergic receptors through activation of the
sympathetic nervous system. Activation of the sym-
pathetic nervous system and RAAS provides an
adaptive response to hypovolemia, hypotension, and
sodium deprivation. This response includes the
release of renin, mostly from granular juxtaglo-
merular cells in the walls of the afferent arterioles of
the kidney, leading to the production of the pressor
angiotensin II. This, in turn, causes vasoconstriction
of renal efferent arterioles, as well as release of
aldosterone, increasing sodium reabsorption in the
collecting duct. However, because these actions are
maladaptive when they occur in patients with HF or
hypertension, reducing the generation of angiotensin
II by ACEi or blocking its action with an ARB are
beneﬁcial in these conditions. In contrast, atrial and/
or ventricular distension, as occurs in HF and hyper-
tension, causes the release of NPs from the heart,
which results in vasodilation and natriuresis.
Although these actions are beneﬁcial (adaptive) in
patients with HF or hypertension, rapid enzymatic
degradation of ANP by endogenous NEP greatly di-
minishes their vasorelaxant, natriuretic, and diuretic
actions. NEPis, while raising the concentration of
circulating vasodilator peptides, especially ANP, have
complex actions (as outlined earlier) and appear by
themselves not to be useful in the treatment of either
HF or hypertension.
VASOPEPTIDASE INHIBITION
Because the previously mentioned elevation of
circulating angiotensin II by NEPi (80,81) neutralizes
its salutary vasorelaxant and natriuretic actions,it appeared logical to ascertain whether the suppres-
sion of angiotensin II production would correct this
problem. In an important study published in 1991,
Seymour et al. (83) compared the separate adminis-
trations of a selective NEPi and of the ACEi captopril,
as well as their simultaneous administration, into
hypertensive rats. As predicted, the combination
resulted in a greater reduction of arterial pressure
than each inhibitor given separately (83). These ob-
servations on the greater efﬁcacy of dual therapy
were conﬁrmed in cardiomyopathic hamsters (84), as
well as in dogs and sheep with pacing-induced HF
(85,86). The next important step was to develop
orally active molecules that inhibited both ACE and
NEP, that is, dual inhibitors. This was accomplished
by Fournie-Zaluski et al. in 1994 (87).
Because of the potential promise of oral dual in-
hibitors, referred to as vasopeptidase inhibitors,
several pharmaceutical companies entered the ﬁeld.
Omapatrilat was the drug in this class that under-
went the most extensive clinical testing (88). It
produced greater reductions in arterial pressure
than did the ACEi, lisinopril, in patients with hy-
pertension and increased the excretion of ANP,
conﬁrming that the dose used also exerted signiﬁ-
cant inhibition of NEP (89). IMPRESS (Inhibition of
Metalloprotease by Omapatrilat in a Randomized
Exercise and Symptoms Study in Heart Failure), a
randomized clinical trial, compared omapatrilat with
lisinopril in 573 patients with HFrEF (90); a strong
trend toward greater beneﬁt with omapatrilat was
reported. These early clinical studies generated
considerable excitement; indeed, in 2001, it was
anticipated that omapatrilat would be launched in
2002 or early 2003, and that annual sales would
quickly approach $2 billion (91).
A phase 3 trial in HF, the OVERTURE (Omapatrilat
Versus Enalapril Randomized Trial of Utility in
Reducing Events) trial led by Packer, compared
omapatrilat with enalapril in 5,770 patients with HF.
There was a nonsigniﬁcant trend for superiority
of omapatrilat in the primary endpoint (all-cause
mortality or hospitalization for HF) and a signiﬁcant
reduction of the secondary endpoint of cardiovascu-
lar death or hospitalization (92). However, angioe-
dema, which can obstruct the upper airways,
occurred more frequently with omapatrilat (0.8%)
than with enalapril (0.5%). In 4,284 hypertensive
subjects in phase 3 trials of omapatrilat, 0.9%
developed angioedema and an additional 1%
developed “head and neck edema” (93). In order to
obtain a clearer understanding of the frequency of
this complication, and, in particular, to compare
omapatrilat with an ACEi, lisinopril, the OCTAVE
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trial was conducted in 25,302 hypertensive subjects.
As expected, omapatrilat was superior to lisinopril in
reducing blood pressure. However, the incidence of
angioedema was again signiﬁcantly higher and more
severe in the subjects treated with omapatrilat
(2.17%) than in those receiving lisinopril (0.68%).
Among African American patients, the incidence was
greater for both agents (5.53% vs. 1.62%) (93). The
increased incidence of this serious, potentially life-
threatening complication was presumed to be
related to the synergism between the ACE- and NEP-
inhibiting actions of omapatrilat on the degradation
of bradykinin (94). Omapatrilat inhibits a third
enzyme, aminopeptidase P, which is also involved in
the breakdown of bradykinin (95). Bradykinin is not
only a vasodilator, but it also enhances prostaglandin
concentrations (19) and increases vascular perme-
ability and ﬂuid extravasation. Hence, the question
was raised as to whether omapatrilat, which initially
appeared to be an attractive drug, could be a “double-
edged sword” (96). Primarily on the basis of obser-
vations of increased angioedema in the OCTAVE trial,
efforts to gain approval of omapatrilat approval and,
indeed, further clinical research on the entire class of
vasopeptidase inhibitors were halted.of LCZ696 on BP
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The next step was to combine the efﬁcacy of vaso-
peptidase inhibitors, that is, suppression of the RAAS
and inhibition of NEP, without their principal adverse
effect, that is, the inhibition of bradykinin and the
resultant angioedema. This was accomplished simply
and cleverly by replacing the ACEi in omapatrilat with
an ARB, because (in contrast to ACEis), ARBs do not
inhibit the breakdown of bradykinin, with a resultant
reduction of the risk of angioedema. In 2003, the
Novartis Pharmaceutical Corporation applied for
the patent of a drug comprising a combination of
the angiotensin antagonist valsartan and an NEPi,
naming Webb and Ksander as the inventors (97).
LCZ696 is a supramolecular complex of 6 molecules of
the ARB valsartan with 6 molecules of the NEPi pro-
drug, sacubitril (AHU377), creating a novel crystalline
complex having a molecular weight of 5,748 (98) and
a ﬁrst-in-class ARNi. Following ingestion, sacubitril is
metabolized rapidly into the active NEPi, LBQ657. Gu
et al. (95) published phase I and II studies on LCZ696
in 2010; the peak concentrations of both valsartan
and LBQ657 occurred at about 3 h following oral
administration. The action of the ARB was reﬂected in
the rapid increases in the plasma renin and angio-
tensin II concentrations. Simultaneously, cyclic gua-
nosine monophosphate rose, reﬂecting an increase in
the concentration of ANP resulting from the NEPi
action of LBQ657.
In 2010, Ruilope et al. (99) compared LCZ696 with
valsartan in 1,328 hypertensive subjects. Systolic,
diastolic, and pulse pressures, both sitting and
ambulatory, fell to a greater extent with LCZ696 than
with either valsartan or the NEPi prodrug (AHU377)
administered separately (Figure 3) (99). LCZ696
was well tolerated, without excess cough and with
no instances of angioedema. Similar ﬁndings were
reported in an Asian population of hypertensive
subjects (100). Solomon et al. (101) conducted the
PARAMOUNT (Prospective comparison of ARNi
with ARB on Management Of heart failUre with pre-
served ejectioN fracTion) trial, a double-blind ran-
domized trial in 301 patients with heart failure
with preserved ejection fraction (HFpEF), which
compared LCZ696 with valsartan. The primary
endpoint, the decline in NT-proBNP at 12 weeks after
treatment was begun, was signiﬁcantly greater in the
LCZ696 group than in the valsartan group (Figure 4).
After 36 weeks, both left atrial volume and dimen-
sion, which reﬂect left ventricular ﬁlling pressure,
also declined more with LCZ696 (Figure 4), and there
was greater improvement in the New York Heart
FIGURE 4 Effects of LCZ696 in HFpEF
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valsartan.
In the PARADIGM-HF trial led by McMurray,
Packer, and other academic investigators collabo-
rating with scientists at Novartis, LCZ696 was
compared to the ACEi enalapril in 8,442 symptomatic
patients with HFrEF. As already noted, the trial was
stopped early for clinical beneﬁt after amedian follow-
up of 27 months (2,6). The hazard ratio for the primary
endpoint (cardiovascular death or hospitalization for
HF), was 0.80; this ratio was also 0.80 for cardiovas-
cular death, was 0.79 for hospitalization for HF, and
was 0.84 for death from any cause. The reductions in
hazard ratios in each of these important endpoints
were highly signiﬁcant (p<0.0001). Over the course of
the trial, the number of patients who needed to be
treated to prevent 1 primary endpoint was 21, and to
prevent 1 cardiovascular death was 32. Although
LCZ696 was associated with symptomatic hypoten-
sion more frequently than was enalapril, this did not
lead to more drug discontinuation. Elevations of
serum creatinine ($2.5mg/dl), potassium (>6mmol/l),
and cough occurred signiﬁcantly less frequently with
LCZ696 than with enalapril. However, there was a
nonsigniﬁcant trend for an increase in angioedema
(without airway compromise) with LCZ696 (n ¼ 19)
compared with enalapril (n ¼ 10; p ¼ 0.13).
In a more recent report, the PARADIGM in-
vestigators (102) indicated that, in comparison with
enalapril, LCZ696 exhibited additional evidence of
clinical beneﬁt, including a reduced need for inten-
siﬁcation of the treatment for HF, fewer visits to an
emergency department for HF, and a lower require-
ment for intensive care or need for inotropic agents,
an HF device, or cardiac transplantation. Progressive
symptoms of HF and elevations of NT-proBNP and
troponin were also reduced.
Although the results of PARADIGM HF are re-
markably robust and promising, after the drug has
been approved, post-marketing observations will be
of interest. Patients in the trial had a run-in period
and were randomized only if they tolerated both
study drugs. Both hypotension and a numeric in-
crease of angioedema with LCZ696 were observed
in PARADIGM HF, but neither led to serious con-
sequences. It will be important to ascertain how
the drug is tolerated when it is used in clinical
practice.
THE FUTURE
HF WITH PRESERVED EJECTION FRACTION. The
PARAMOUNT study (101) served as a hypothesis-
generating trial for HFpEF. Given PARAMOUNT’sencouraging results (Figure 4), the PARAGON (Pro-
spective Comparison of LCZ696 with ARB Global
Outcome in HF with Preserved Ejection Fraction)
trial (NCT01920711) has begun. It is intended to
enroll 4,300 patients with left ventricular ejection
fraction >45%.
RENAL DISEASE. There is now good evidence that
blockade of the RAAS by either ACEi or ARB slows
progression in patients with chronic kidney disease,
with and without diabetes (103,104). The NEPi, can-
doxatrilat, has been shown to be associated with
natriuresis in patients with moderate impairment of
renal function (105). Studies in partially nephrec-
tomized rats (106) and in rats with diabetic ne-
phropathy (107) have demonstrated that the
vasopeptidase inhibitor, omapatrilat, was superior to
an ACEi in slowing the progression of renal injury in
the remaining renal tissue. In both the IMPRESS (90)
and OVERTURE (92) trials, omapatrilat was associ-
ated with signiﬁcantly fewer instances of worsening
renal function than the ACEi comparator. Similar
ﬁndings were observed with LCZ696 in the PARA-
MOUNT trial (101). Also, in the PARADIGM-HF trial,
which excluded patients with an estimated glomer-
ular ﬁltration rate <30 ml/min, fewer patients on
LCZ696 developed a serum creatinine level$2.5 mg/dl
(n ¼ 139, 3.3%) than did patients on enalapril (n ¼ 188,
4.5%; p ¼ 0.007) (6).
Braunwald J A C C V O L . 6 5 , N O . 1 0 , 2 0 1 5
Angiotensin-Neprilysin Inhibition in Heart Failure M A R C H 1 7 , 2 0 1 5 : 1 0 2 9 – 4 1
1038The totality of this information suggests that
LCZ696 may be superior to blockers of the RAAS on
renal function. This is being tested prospectively in
the UKHARP (UK Heart and Renal Protection) III trial
(ISRCTN11958993), which is comparing LCZ696 with
the ARB, irbesartan, in patients with proteinuric renal
disease and an estimated glomerular ﬁltration
rate $20 and <60 ml/min/1.73 m2 (108). Furthermore,
because HF is a common, serious complication in
patients with end-stage renal disease, LCZ696 might
retard the development and/or progression of both
conditions.
AORTIC STIFFNESS. In the elderly, the stiffness of
the aorta and large arteries raises the systolic blood
pressure, pulse pressure, and pulse wave velocity, all
3 of which are independent predictors of adverse
cardiac events (109,110) and of the progression of renal
disease (111). It has been shown that noninvasively
determined central aortic blood pressure is superior
to brachial arterial pressures in estimating cardiovas-
cular risk (112). In the Strong Heart study, central
(aortic root) systolic pressure was a potent predictor of
left ventricular hypertrophy, whereas pulse pressure
was a predictor of vascular hypertrophy (113). In 2002,
Mitchell et al. (114) demonstrated the superiority of
omapatrilat over enalapril in reducing both central
aortic and peripheral arterial pulse pressures, reﬂect-
ing a reduced stiffness of the aorta, perhaps brought
about by the elevation of circulating ANP consequent
to the NEPi activity of omapatrilat.
In the aforementioned study of hypertensive sub-
jects, LCZ696 reduced both ambulatory systolic and
pulse pressures more than did valsartan (99), a
ﬁnding that is compatible with a reduction of aortic
stiffness. Accordingly, the PARAMETER (Prospective
comparison of Angiotensin Receptor neprilysin in-
hibitor with Angiotensin receptor blocker Measuring
arterial stiffness in the Elderly) study (NCT01692301)
is comparing LCZ696 with an ARB (olmesartan) in 432
elderly (age $60 years) hypertensive patients with a
pulse pressure >60 mm Hg (109). The endpoints are
changes in central aortic systolic and pulse pressures
determined noninvasively (115). LCZ696 is also
promising for the treatment of serious and/or resis-
tant hypertension.CONCLUSIONS
The unambiguous superiority of clinical outcomes in
patients with HFrEF by the ﬁrst ARNi over enalapril in
the PARADIGM HF trial (6,102,116) represents a sig-
niﬁcant achievement with important clinical impli-
cations. LCZ696 may replace conventional ACEis or
ARBs in many patients with chronic HFrEF. The po-
tential value of LCZ696 in HFpEF; in acute HF; in HF
patients with the cardiorenal syndrome; in the pre-
vention of HF in asymptomatic patients with left
ventricular hypertrophy, dilation, and/or dysfunc-
tion; and in severe hypertension remains to be
determined.
LCZ696 developed from the stepwise research
described herein (Figure 1). Progress was slow in the
ﬁrst half of the 20th century, but it then accelerated
progressively, especially after de Bold’s important
discovery in 1981 (34). Academic scientists carried
out the initial work deﬁning the components of both
the RAAS and the NPS, some of whom conducted
early experiments on blocking these systems. Once it
was realized that blockade was potentially of great
clinical value, the pharmaceutical industry stepped
in and provided enormous talent and resources to
move the ﬁeld forward. Millions of patients with
hypertension and HF worldwide have beneﬁted from
ACEis and ARBs, which are among the most useful
drugs in the pharmacopeia. The most recent advance,
the development and clinical assessment of a drug
that simultaneously blocks the RAAS, inhibits the
breakdown of vasodilator peptides, and appears to be
well tolerated, is an excellent example of the syn-
ergies that can result from academic-industrial
collaborations.
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